The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates to Axial Spondyloarthritis Guideline

Updates to Axial Spondyloarthritis Guideline

September 5, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The availability of new medications to treat axial spondyloarthritis (axSpA), including medications recently approved by the U.S. Food and Drug Administration to treat ankylosing spondylitis (AS)—secukinumab and ixekizumab—as well as new evidence on tapering and discontinuing biologics, magnetic resonance imaging (MRI) and radiograph imaging are the driving forces behind the release of a revised guideline for ankylosing spondylitis. The new guideline, “2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [nr-axSpA],” is now available online.1

You Might Also Like
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
Also By This Author
  • Reap the Rewards of State Society Involvement

AxSpA (including both AS and nr-axSpA) is the main form of chronic inflammatory arthritis affecting the axial skeleton. As many as 2.7 million adults may be affected by the disease, which is characterized by back and hip pain, peripheral joint pain and fatigue.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The 2019 guideline includes 86 recommendations presented by the ACR, in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), to provide updated and new guidance for the management of patients with AS and nr-axSpA in the areas of pharmacologic and non-pharmacologic treatment options, AS-related co-morbidities, disease activity assessment, imaging and screening.

“New medications to treat axial spondyloarthritis, most notably interleukin 17A (IL-17A) inhibitors, secukinumab and ixekizumab, are now supported by large, published clinical trials that demonstrated efficacy in AS, so we thought it was important to update the recommendations to accommodate this new information,” says Michael Ward, MD, lead investigator of the guideline update.3,4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Early studies on tofacitinib and an expanding number of tumor necrosis factor inhibitor (TNFi) biosimilars, as well as recommendations on some other topics, such as imaging, were also considered in the update.

Guideline Updates at a Glance
To revise the guideline, Dr. Ward and the panel of co-authors updated the systematic literature review for 20 clinical questions on pharmacologic treatment addressed in the 2015 guideline and conducted a new literature review for 26 new questions on pharmacologic treatment, treat-to-target strategies and use of imaging. New questions addressed the use of secukinumab, ixekizumab, tofacitinib, TNFi biosimilars and biologic tapering and discontinuation, among other factors. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and formulate recommendations. At least 70% agreement among the guideline voting panel was required for a recommendation to be included in the guideline.

The 2019 recommendations for AS and nr-axSpA are similar to the earlier guideline. Many of the recommendations are conditional instead of strong, driven mainly by the fact that little evidence in the literature supports the recommendation and future evidence may contradict it. Among the recommendations:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Guidelines, Spondyloarthritis Tagged With: Ankylosing Spondylitis, AS Resource Center, axial spondyloarthritis (SpA), Clinical Guidelines, Michael Ward

You Might Also Like:
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
  • NSAIDs Effective for Early Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)